The Human LAT1-4F2hc (SLC7A5-SLC3A2) Transporter Complex: Physiological and Pathophysiological Implications

Overview

Journal Basic Clin Pharmacol Toxicol

Specialties Pharmacology
Toxicology

Date 2022 Dec 2

PMID 36460306

Authors

Jennifer Kahlhofer

David Teis

Affiliations

Soon will be listed here.

Abstract

LAT1 and 4F2hc form a heterodimeric membrane protein complex, which functions as one of the best characterized amino acid transporters. Since LAT1-4F2hc is required for the efficient uptake of essential amino acids and hormones, it promotes cellular growth, in part, by stimulating mTORC1 (mechanistic target of rapamycin complex 1) signalling and by repressing the integrated stress response (ISR). Gain or loss of LAT1-4F2hc function is associated with cancer, diabetes, and immunological and neurological diseases. Hence, LAT1-4F2hc represents an attractive drug target for disease treatment. Specific targeting of LAT1-4F2hc will be facilitated by the increasingly detailed understanding of its molecular architecture, which provides important concepts for its function and regulation. Here, we summarize (i) structural insights that help to explain how LAT1 and 4F2hc assemble to transport amino acids across membranes, (ii) the role of LAT1-4F2hc in key metabolic signalling pathways, and (iii) how derailing these processes could contribute to diseases.

Citing Articles

Primary Roles of Branched Chain Amino Acids (BCAAs) and Their Metabolism in Physiology and Metabolic Disorders.

Bo T, Fujii J Molecules. 2025; 30(1.

PMID: 39795113 PMC: 11721030. DOI: 10.3390/molecules30010056.

Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression.

Onagi A, Sugimoto K, Kobayashi M, Sato Y, Kobayashi Y, Yaginuma K Cell Commun Signal. 2024; 22(1):588.

PMID: 39639312 PMC: 11619122. DOI: 10.1186/s12964-024-01964-5.

Regulatory Role of eIF2αK4 in Amino Acid Transporter Expression in Mouse Brain Capillary Endothelial Cells.

Hamada Y, Masuda T, Ito S, Ohtsuki S Pharm Res. 2024; 41(11):2213-2223.

PMID: 39532778 DOI: 10.1007/s11095-024-03793-0.

Branched-chain amino acids: physico-chemical properties, industrial synthesis and role in signaling, metabolism and energy production.

Reifenberg P, Zimmer A Amino Acids. 2024; 56(1):51.

PMID: 39198298 PMC: 11358235. DOI: 10.1007/s00726-024-03417-2.

Claudin-4 Modulates Autophagy via SLC1A5/LAT1 as a Mechanism to Regulate Micronuclei.

Villagomez F, Lang J, Rosario F, Nunez-Avellaneda D, Webb P, Neville M Cancer Res Commun. 2024; 4(7):1625-1642.

PMID: 38867360 PMC: 11218812. DOI: 10.1158/2767-9764.CRC-24-0240.

References

Lynch C, Adams S . Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014; 10(12):723-36. PMC: 4424797. DOI: 10.1038/nrendo.2014.171. View

Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H . Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. Radiology. 2001; 220(1):54-62. DOI: 10.1148/radiology.220.1.r01jl1654. View

Hayashi K, Kaminuma O, Nishimura T, Saeki M, Matsuoka K, Hiroi T . LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation. Allergy. 2019; 75(2):463-467. DOI: 10.1111/all.14019. View

Elorza A, Soro-Arnaiz I, Melendez-Rodriguez F, Rodriguez-Vaello V, Marsboom G, de Carcer G . HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012; 48(5):681-91. DOI: 10.1016/j.molcel.2012.09.017. View

Nakamura E, Sato M, Yang H, Miyagawa F, Harasaki M, Tomita K . 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem. 1999; 274(5):3009-16. DOI: 10.1074/jbc.274.5.3009. View

Cormerais Y, Pagnuzzi-Boncompagni M, Schrotter S, Giuliano S, Tambutte E, Endou H . Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med. 2019; 23(4):2711-2718. PMC: 6433660. DOI: 10.1111/jcmm.14176. View

Yamamoto Y, Sawa R, Wake I, Morimoto A, Okimura Y . Glucose-mediated inactivation of AMP-activated protein kinase reduces the levels of L-type amino acid transporter 1 mRNA in C2C12 cells. Nutr Res. 2017; 47:13-20. DOI: 10.1016/j.nutres.2017.08.003. View

Hayashi K, Jutabha P, Endou H, Anzai N . c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. Oncol Rep. 2012; 28(3):862-6. DOI: 10.3892/or.2012.1878. View

Fontana L, Cummings N, Arriola Apelo S, Neuman J, Kasza I, Schmidt B . Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health. Cell Rep. 2016; 16(2):520-530. PMC: 4947548. DOI: 10.1016/j.celrep.2016.05.092. View

10.

Saxton R, Knockenhauer K, Wolfson R, Chantranupong L, Pacold M, Wang T . Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science. 2015; 351(6268):53-8. PMC: 4698039. DOI: 10.1126/science.aad2087. View

11.

Barthelemy C, Andre B . Ubiquitylation and endocytosis of the human LAT1/SLC7A5 amino acid transporter. Sci Rep. 2019; 9(1):16760. PMC: 6856120. DOI: 10.1038/s41598-019-53065-w. View

12.

Ardestani A, Lupse B, Kido Y, Leibowitz G, Maedler K . mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells. Cell Metab. 2017; 27(2):314-331. DOI: 10.1016/j.cmet.2017.11.004. View

13.

Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Luhovyy B . Brain amino acid requirements and toxicity: the example of leucine. J Nutr. 2005; 135(6 Suppl):1531S-8S. DOI: 10.1093/jn/135.6.1531S. View

14.

Kobayashi N, Okazaki S, Sampetrean O, Irie J, Itoh H, Saya H . CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake. Sci Rep. 2018; 8(1):2785. PMC: 5809395. DOI: 10.1038/s41598-018-20973-2. View

15.

Chien H, Colas C, Finke K, Springer S, Stoner L, Zur A . Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018; 61(16):7358-7373. PMC: 6668346. DOI: 10.1021/acs.jmedchem.8b01007. View

16.

Kanai Y . Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther. 2021; 230:107964. DOI: 10.1016/j.pharmthera.2021.107964. View

17.

Beckers M, Bloem B, Verbeek M . Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):56. PMC: 9095610. DOI: 10.1038/s41531-022-00321-y. View

18.

Sato M, Harada-Shoji N, Toyohara T, Soga T, Itoh M, Miyashita M . L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Sci Rep. 2021; 11(1):589. PMC: 7803739. DOI: 10.1038/s41598-020-80668-5. View

19.

Boado R, Li J, Nagaya M, Zhang C, Pardridge W . Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A. 1999; 96(21):12079-84. PMC: 18415. DOI: 10.1073/pnas.96.21.12079. View

20.

Cangelosi A, Puszynska A, Roberts J, Armani A, Nguyen T, Spinelli J . Zonated leucine sensing by Sestrin-mTORC1 in the liver controls the response to dietary leucine. Science. 2022; 377(6601):47-56. PMC: 10049859. DOI: 10.1126/science.abi9547. View